Valo Health and Novo Nordisk expand collaboration to discover and develop novel treatments for cardiometabolic diseases
Scope of collaboration originally signed in 2023 will significantly expand to enable the discovery and development of up to ...
As demand for weight-loss drugs rises, states grapple with Medicaid coverage
Over her three-decade career, weight management physician Dr. Sarah Ro has seen hundreds of patients. Many of them are on ...
Novo Nordisk, Valo Health Expand Drug Discovery and Development Pact
The deal expands a deal to discover and develop treatments for obesity, type 2 diabetes and cardiovascular disease using ...
BioSpace55m
Novo Puts $4.6B on the Line to Expand Valo Deal, Maintain Cardiometabolic Leadership
The investment continues a Novo dealmaking spree to cement its leadership status in the cardiometabolic space, with ...
Ozempic maker Novo Nordisk, after trial disappointment, expands AI deal in potential $4.6 billion pact
At least four analysts weighed in on the prospects for Europe’s second-largest company, Novo Nordisk, after the Danish drugmaker reported disappointing results for its next-generation weight-loss drug ...
Americans Are Dying Too Young -- US Health Policy Needs a Shakeup
The American public is being sold a bill of goods that enrolling everyone in government-approved health insurance -- ...
Taiwan News25m
Standard BioTools SomaScan Assay Powers Key Insights into Semaglutide Treatment Published in Nature Medicine
SOUTH SAN FRANCISCO, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company”) announced today that its SomaScan™ Platform played a pivotal role in a study ...
pharmaphorum16m
11 blockbuster drugs to look out for in 2025
Drugs for metabolic diseases, vaccines and cancer therapies feature among new product launches this year that could top $1 ...